Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$418.76M+67.28%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stuart Essig
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 4,427
- Beta
- 1.21
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.23
Financials
Revenue
$418.76M+67.3%Net Income
$4.48M-77.8%EBITDA
$65.87M+12.4%Free Cash Flow
$37.65M-5.4%EPS (diluted)
$0.06-76.0%Shares Outstanding (diluted)
78.17M-3.5%Operating Expenses
$196.69MCash & Debt
$274.08MReturn of Capital
$0.00Revenue by Segment (annual)
$1.64BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.64B | $-516.47M | $-6.73 |
| 2024 | $1.61B | $-6.94M | $-0.09 |
| 2023 | $1.54B | $67.74M | $0.87 |
| 2022 | $1.56B | $180.55M | $2.18 |
| 2021 | $1.54B | $169.07M | $2.00 |
| 2020 | $1.37B | $133.89M | $1.58 |
| 2019 | $1.52B | $50.20M | $0.59 |
| 2018 | $1.47B | $60.80M | $0.73 |
| 2017 | $1.19B | $64.74M | $0.83 |
| 2016 | $992.08M | $74.56M | $1.00 |
| 2015 | $882.73M | $-3.52M | $-0.05 |
| 2014 | $928.30M | $34.00M | $0.52 |
| 2013 | $836.21M | $-16.98M | $-0.30 |
| 2012 | $830.87M | $41.20M | $0.74 |
Valuation
IARThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
55-31.25%Social Signal Score
Mentions (14)
- Newsglobenewswire.com·12h ago·Neutral
INTEGRA LIFESCIENCES HOLDINGS CORPORATION INVESTIGATION: IART Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in othe…
View source ↗ - Newsprnewswire.com·3d ago·Neutral
Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART) A $4.3 million to $6.3 million gap between Integra's preliminary third-quarter revenue and the Wall Street estimate sent IART shares lower. SueWallSt notifies investors of a pending investigation into potential securities claims for shareholders who lost money.
View source ↗ - Newsproactiveinvestors.com·3d ago·Positive
Integra LifeSciences lowers revenue and earnings outlook for 2026 Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion.
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.
View source ↗ - Newsglobenewswire.com·4d ago·Negative
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction.
View source ↗ - Newszacks.com·4d ago·Neutral
IART vs. PEN: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newszacks.com·5d ago·Neutral
Should You Continue to Hold IART Stock in Your Portfolio? Integra sees steady Specialty Surgery demand and improving efficiency, but leverage and currency swings remain key challenges for Integra.
View source ↗ - Newszacks.com·6d ago·Positive
IART or PEN: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026 Company to feature surgeon-led educational programming and technologies supporting liver surgery Company to feature surgeon-led educational programming and technologies supporting liver surgery
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·33d ago·Positive
Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis Integra LifeSciences Holdings is a turnaround story, maintaining a BUY rating after a strong 2Q26 earnings beat and margin expansion. IART's specialty surgery segment led revenue, while tissue reconstruction saw declines offset by a successful PriMatrix relaunch and upcoming SurgiMend reintroduction. Management targets leverage reduction to 2.5–3.5x by end-2026, prioritizing debt repayment as operating cash flow improves.
View source ↗ - Newszacks.com·46d ago·Neutral
Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery? Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.
View source ↗ - Newszacks.com·47d ago·Positive
Is IART Still Attractive as Its Low Valuation Meets Execution Risks? Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $0.56 per share
Typical surprise +12.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.56 vs $0.48beat
- Tue, May 5$0.54 vs $0.41beat
- Thu, Feb 26$0.83 vs $0.79beat
- Thu, Oct 30$0.54 vs $0.43beat
- Thu, Jul 31$0.45 vs $0.43beat
- Mon, May 5$0.41 vs $0.43miss
Estimates and results for IART via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IART officers and directors.
- Bought
- $102k
- Sold
- —
1 trade
0 trades
- Graves Jeffrey Abought
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (21d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 15, 2024 (40d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (26d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 11, 2023 (28d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (20d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 13, 2020 (28d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (474d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 16, 2020 (37d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Mar 16, 2020 (42d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Mar 10, 2020 (29d later)Buy$1,001 - $15,000
- Thomas Roland Tillissenate · NC · disclosed Feb 26, 2015 (13d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.